Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 207

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 207
---
 |  Page 44

Product Portfolio and Internal Pipeline

Our current product portfolio and internal product candidate pipeline, along with anticipated milestones over the next 12 to 18 months, are summarized in the table below:

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 45

Results of Operations

Comparison of the Three and Six Months Ended June 30, 2025 and 2024 

Revenues

Net product sales consist of sales of (i) EXPAREL in the U.S., E.U., and the United Kingdom; (ii) ZILRETTA in the U.S.; (iii) iovera° in the U.S., Canada and the E.U. and (iv) sales of our bupivacaine liposome injectable suspension product for veterinary use. Royalty revenues are related to a collaborative licensing agreement from the sale of our bupivacaine liposome injectable suspension for veterinary use.

The following table provides information regarding our revenues during the periods indicated, including percent changes (dollar amounts in thousands):

Three Months EndedJune 30,% Increase / (Decrease)Six Months EndedJune 30,% Increase / (Decrease)2025202420252024Net product sales:EXPAREL$142,917 $136,852 4%$279,446 $269,282 4%ZILRETTA31,334 30,707 2%54,672 56,546 (3)%iovera°5,588 5,674 (2)%10,711 10,704 0%Bupivacaine liposome injectable suspension508 3,154 (84)%3,112 5,679 (45)%Total net product sales180,347 176,387 2%347,941 342,211 2%Royalty revenue752 1,636 (54)%2,081 2,929 (29)%Total revenues$181,099 $178,023 2%$350,022 $345,140 1%

EXPAREL revenue increased 4% in both the three and six months ended June 30, 2025 versus 2024. Components of the increase included a 6% and 4% increase in gross vial volume in the three and six months ended June 30, 2025 versus 2024, respectively